Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
infliximab-dyyb
- Development stage
- Approved
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Infliximab-dyyb is a biosimilar to infliximab (Remicade), classified as a tumor necrosis factor (TNF) inhibitor. It is a chimeric human-murine IgG1 monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting its activity. This mechanism reduces inflammation and immune-mediated tissue damage in autoimmune diseases. Infliximab-dyyb is indicated for the treatment of moderate to severe Crohn's disease and ulcerative colitis in adults (and children for some indications), rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. The drug is available as both intravenous infusion (Inflectra) and subcutaneous injection (Zymfentra). It was developed by Celltrion as the first biosimilar to Remicade approved in the US[1][5][6][7][9][10].
- Brand names
- InflectraZymfentra
- Other names
- infliximab-dyybInflectraZymfentraCT-P13CT-P-13CT-P 13
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on infliximab-dyyb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on infliximab-dyyb.